UCB SA (OTCMKTS:UCBJY – Get Free Report) was the recipient of a significant decrease in short interest in the month of October. As of October 30th, there was short interest totaling 7,614 shares, a decrease of 63.8% from the October 15th total of 21,017 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 76,592 shares, the days-to-cover ratio is currently 0.1 days.
Analyst Ratings Changes
A number of equities analysts have recently commented on UCBJY shares. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 27th. Two research analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, UCB currently has an average rating of “Buy”.
View Our Latest Research Report on UCBJY
UCB Trading Up 0.8%
Shares of OTCMKTS:UCBJY traded up $1.34 during midday trading on Friday, hitting $163.75. The company’s stock had a trading volume of 14,056 shares, compared to its average volume of 31,350. The stock’s 50 day simple moving average is $131.08 and its 200 day simple moving average is $140.66. UCB has a fifty-two week low of $110.55 and a fifty-two week high of $168.76.
About UCB
UCB is a Belgian biopharmaceutical company headquartered in Brussels. Founded in 1928, it develops medicines for people with serious neurological and immune-mediated diseases, with research focused on areas such as epilepsy and inflammatory conditions. Its products include epilepsy treatments such as Briviact and Vimpat, as well as medicines for immune-mediated diseases, including Bimzelx and Cimzia. Product availability and approved uses vary by country. UCB serves patients and healthcare providers across international markets through its global operations.
See Also
- Five stocks we like better than UCB
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
